A novel fungus concentration-dependent rat model for acute invasive fungal rhinosinusitis: an experimental study

Yuyan Yan¹, Zuotao Zhao², Hongfei Wan¹, Ruochen Wu¹, Jugao Fang³ and Honggang Liu¹*

Abstract

Background: Acute invasive fungal rhinosinusitis is a lethal infectious process afflicting immunocompromised individuals. Knowledge about this disease is still limited due to the scarcity of animal models designed to study the pathogenesis of this infection. Mast cells are tissue-resident immune cells that participate in a variety of allergic and inflammatory conditions. Limited attention has been given to the role of mast cells in acute invasive fungal rhinosinusitis. Therefore, the objectives of this study were to create a rat model of acute invasive fungal rhinosinusitis based on analyzing the impact of different fungal concentrations on establishing infection, and to observe the changes of mast cells in rats with this disease.

Methods: Sprague–Dawley rats were divided randomly into four groups, three of which were experimental and received different concentrations of Aspergillus fumigatus inoculations, and one was a control group (D). The inoculated Aspergillus fumigatus concentrations were $5 \times 10^7$ conidia/ml in group A, $10^7$ conidia/ml in group B, and $10^6$ conidia/ml in group C. Before fungal inoculation, rats were immunosuppressed using cyclophosphamide and cortisone acetate, and had Merocel sponges inserted into the right nares. Hematology and histopathology investigations were then performed.

Results: An acute invasive fungal rhinosinusitis rat model was established successfully with an incidence rate of 90% in group A, 50% in group B and 10% in group C. Aspergillus fumigatus invasion was observed in 20% of the lungs in group A, but was not seen in the remaining groups. In addition, no fungi invaded the orbital tissue, brains, livers, spleens or kidneys of any rat. Compared with the control set, the total number of mast cells in the experimental groups was not significantly increased, but mast cell degranulation, on the other hand, was only found in infected nasal cavities.

Conclusions: This investigation illustrates that various fungal concentrations have different effects on the incidence of acute invasive fungal rhinosinusitis, and it also demonstrates the feasibility of using this model to study the process of fungal rhinosinusoidal invasion. In addition, the results suggest that mast cells may play a role in the protection of sinuses against acute Aspergillus fumigatus infection and in the clearance of established hyphal masses.

Keywords: Acute invasive fungal rhinosinusitis, Animal model, Aspergillus fumigatus, Mast cells

Background

Acute invasive fungal rhinosinusitis (AIFR) is an aggressive fungal infection with high mortality rates (50%–80%) in immunocompromised patients [1,2]. It is characterized by fungal invasion into the mucosa and submucosal structures of the nasal cavity or paranasal sinuses with frequent extension into adjacent structures, including the nasal soft tissue, vasculature, orbit, and cranium [3-5]. Hematological–oncological malignancies, aplastic anemia, uncontrolled diabetes mellitus, and acquired immune deficiency syndrome (AIDS) are the most common predisposing diseases for AIFR [6-9]. In addition, long-term steroid treatment and the utilization of chemotherapy agents and immunosuppressants, which are used after bone marrow and solid organ transplantations, are important risk factors [10-12].

At present, animal models designed for the study of sinusitis are limited to bacteria [13-17]. For fungal infections, most studies focus on pulmonary aspergillosis and...
noninvasive fungal sinusitis [18–23]. Only two papers presenting an AIFR animal model are currently published [5,24]. Due to the lack of an established AIFR animal model that closely mimics the pathophysiology of infection in addition to providing ease of operation, most AIFR research has been limited to clinical observations [2,3,12,25]. Mast cells (MCs) are leukocytes that are derived from haematopoietic progenitor cells. They are long-lived and reside in most tissues of the body, particularly in locations that are in close contact with the external environment, such as skin, airways, and intestines, where they can initiate and enhance early responses to environmental threats, including pathogens [26]. MCs are preferentially located in the vicinity of blood vessels, nerves, and lymphatic vessels, where they can regulate vascular permeability and instigate effector cell recruitment by releasing preformed as well as de novo synthesized mediators [27]. MCs are also important effector cells in allergic diseases and protective immune responses against pathogens, with roles in both innate and adaptive immunity, including the direct killing of organisms [28–32]. Because the majority of MC research focuses on bacteria, the role of MCs in the pathogenesis of fungal infections is poorly understood. A single in vitro study found that Aspergillus fumigatus hyphae induced degranulation of MCs via an IgE independent mechanism [33]. In normal subjects and those with nonallergic rhinitis, there are few MCs in the epithelial compartment of the nasal mucosa. Studies have found that the number of MCs increases in allergic rhinitis and nasal polyps [34–36]. Currently, it is still unclear what types of changes are occurring in the MC population in AIFR.

The focus of our study was to create a novel AIFR rat model by analyzing the impact of different fungal concentrations on AIFR establishment, and then to use this model to explore the role that MCs may play in the disease process. In order to develop a novel animal model of AIFR that is stable and clinically relevant, we tested numerous immunosuppression regimens and various concentrations of fungal spores. The intranasal infection model reported here illustrates that various concentrations of fungi have different effects on AIFR incidence. With the appropriate concentration of fungi, an AIFR model that is stable and clinically relevant can be established in the immunosuppressed rat, and this model can be used to study immune factors, such as MCs, related to AIFR.

**Methods**

**Rats and groups**

Forty female Sprague–Dawley (SD) rats aged 6–8 weeks and weighing 230 ± 10 g were used. They were housed in pathogen-free conditions in the Animal Laboratory of the First Affiliated Hospital of General Hospital of Chinese People’s Liberation Army (PLA) of Beijing, and the rats were given food and water at all times. All procedures and animal care were conducted in accordance with guidelines set forth by the Institutional Animal Care & Use Committee (IACUC) of First Hospital Affiliated to PLA General Hospital and adhere to Reporting In Vivo Experiments (ARRIVE) guidelines (http://www.nc3rs.org.uk/page.asp?id=1357). The animal study was approved by the Institutional Animal Care & Use Committee (IACUC) of First Hospital Affiliated to PLA General Hospital.

Rats were randomly divided into four groups of 10. Table 1 shows the interventions for each group. The model was established in three consecutive steps: 1) Cyclophosphamide (CPA) and cortisone acetate (CA) were administered, 2) Unilateral nasal cavities were obstructed with Merocel sponges (Medtronic Xomed, Jacksonville, FL), and 3) Nasal cavities were inoculated with A. fumigatus. The different experimental groups were inoculated with various concentrations of A. fumigatus: group A received $5 \times 10^7$ conidia/ml, group B $1 \times 10^7$ conidia/ml, and group C $1 \times 10^6$ conidia/ml. Group D was the control group and received no treatment.

**Immunosuppression**

Based on many preliminary experiments, we chose cyclophosphamide (Sigma, America) [37,38] and cortisone acetate suspension (Sigma, America) [39–41] as immune inhibitors to establish immunosuppressed rats before nasal obstruction and fungal inoculation.

Table 2 shows the doses, timing and methods of cyclophosphamide and cortisone acetate delivery. Five days before the first administration of A. fumigatus (D-5), rats in groups A, B and C were given an intraperitoneal injection (ip) of CPA at a dose of 75 mg/kg and a subcutaneous injection (sc) of CA at a dose of 80 mg/kg.

| Table 1 Groups and interventions |
|-------------------------------|-----------------|
| **Group** | **n** | **Intervention** |
| A | 10 | Administration of immune inhibitors with nasal obstruction and fungal inoculation of $5 \times 10^7$ conidia/ml concentration |
| B | 10 | Administration of immune inhibitors with nasal obstruction and fungal inoculation of $10^7$ conidia/ml concentration |
| C | 10 | Administration of immune inhibitors with nasal obstruction and fungal inoculation of $10^6$ conidia/ml concentration |
| D | 10 | No treatment (negative control) |

n: Number of rats in each group.
day before the first administration of *A. fumigatus* (D-1), rats in groups A through C were given a CPA ip at a dose of 60 mg/kg and a CA sc at a dose of 80 mg/kg. The last injections of CPA at a dose of 50 mg/kg and CA at a dose of 80 mg/kg were given two days after the first administration of *A. fumigatus* (D + 2).

For the neutrophil count analysis, whole blood samples (0.1 ml) were collected from the angular veins of all rats on D-5, the first administration day of *A. fumigatus* spores (D0), and the fourth day after the first administration of *A. fumigatus* (D + 4). The blood counts were analyzed with SYSMEX XS-820 (Japan) in the Laboratory of Beijing Tongren Hospital.

**Fungi inoculum**

*A. fumigatus* strain (AF9732 wild strain from the Fungi and Fungal Disease Research Center of Peking University) was grown on potato dextrose agar (PDA) plates at 37°C for 5 days. Conidia were harvested by washing the plates with sterile 0.2% Tween 20, followed by centrifugation and filtration of the suspension through eight layers of sterile gauze to remove hyphae. The conidia were subsequently diluted and counted with a hemocytometer to obtain $5 \times 10^7$, $1 \times 10^7$, and $1 \times 10^6$ conidia/ml suspensions.

**Nasal obstruction and intranasal inoculation of *A. Fumigatus* conidia**

On the second day after the second injection of CPA and CA, rats in experimental groups were anesthetized with intraperitoneal injections of 3% pentobarbital sodium (Sigma, America) at 40 mg/kg. A piece of Merocel sponge was inserted 1.5 cm deep into the right nasal cavities. Then a suspension of 100 μl of *A. fumigatus* conidia was dropped into the right nasal cavity, with a concentration of $5 \times 10^7$ conidia/ml in group A, $1 \times 10^7$ conidia/ml in group B, and $1 \times 10^6$ conidia/ml in group C (Figure 2). These fungal inoculations were performed for three consecutive days.

**Histopathology analysis**

Rats were euthanized with a respiratory-failure dose of 120 mg/kg of pentobarbital sodium (Sigma, America) given by intraperitoneal injection four days after the first administration of *A. fumigatus* conidia. The rats were then decapitated. The skin on the heads was divested and the mandibles were removed. The specimens were soaked in 10% neutral paraformaldehyde for 24 hours. This was followed by decalcification with decalcifying fluid (0.5 mol/L ethylenediaminetetraacetic acid (EDTA), PH 7.4) for one month until soft. The heads were subsequently cut coronally for 2 mm and made into wax blocks, sectioned at 3 μm thickness, and stained with hematoxylin and eosin (HE), Periodic acid-Schiff (PAS), methenamine silver and MUC5B for visualization of the fungi.

Lungs, livers, kidneys and spleens were also extracted for histopathological examination with HE staining.

**Toluidine blue staining**

To assist in differentiating MCs from other inflammatory cells, toluidine blue staining was used in this study.

---

**Table 2 Rat immunosuppressant doses (mg/kg)**

| Immunosuppressant | D-5 | D-1 | D + 2 |
|-------------------|-----|-----|-------|
| CPA (ip)          | 75  | 60  | 50    |
| CA (sc)           | 80  | 80  | 80    |

CPA: Cyclophosphamide; CA: Cortisone acetate; D-5: Five days before the first administration of *A. fumigatus* spores; D-1: One day before the first administration of *A. fumigatus* spores; D + 2: Two days after the first administration of *A. fumigatus* spores; ip: Intraperitoneal injection; sc: Subcutaneous injection.
Serialized 3 μm-thick sections were deparaffinized, rehydrated, and stained with 0.5% toluidine blue. These sections were stored at 4°C for one night, and subsequently underwent glacial acetic acid differentiation and vitrification by dimethylbenzene. MCs were identified by deep blue staining.

Immunohistochemical staining for mast cells
Immunohistochemistry was performed using the horse-radish peroxidase (HRP) immunohistochemical method. Tissue sections (3 μm) were deparaffinized and rehydrated in distilled water. Endogenous peroxidase activity was blocked by incubation with 0.3% hydrogen peroxide for 10 minutes at room temperature. Antigen retrieval was performed by cooking the sections in citrate solution for 2–3 minutes. The tissue sections were then incubated with antimast cell tryptase antibody (AA1IgG1; 1:2000 dilutions) for 35 minutes in a 37°C water bath box. They were then washed a final time in distilled water and PBS (pH 7.4) before diaminobenzidine (DAB) coloration. Lastly, the slides were counterstained with hematoxylin after rinsing with water. MCs were identified by deep blue staining.

Statistics
Statistical analyses were performed using SPSS 17.0 (SPSS, Inc., America, English). Comparisons across interventions were evaluated using Chi-square test and repeated measures analysis of variance (REP ANOVA). P-values less than 0.05 were considered to be statistically significant.

Results
The rats were diagnosed with AIFR if histopathology revealed the presence of *A. fumigatus* hyphae within nasal tissue. During the entire length of the experiment, the Merocel sponges demonstrated no prolapse by remaining in the nostrils of all rats.

| Group | n | D-5 | D-1 | D0 | D + 2 | D + 3 | D + 4 |
|-------|---|-----|-----|----|------|------|------|
| A     | 10 | 237.0 ± 14.58 | 226.9 ± 8.76 | 220.4 ± 8.90 | 207.9 ± 19.50 | 199.7 ± 16.70 | 199.2 ± 23.11 |
| B     | 10 | 242.4 ± 12.60 | 236.6 ± 11.34 | 224.0 ± 10.17 | 211.1 ± 9.82 | 203.4 ± 7.23 | 199.0 ± 11.62 |
| C     | 10 | 241.3 ± 2.43 | 233.0 ± 9.26 | 222.1 ± 8.75 | 213.6 ± 12.00 | 201.3 ± 12.50 | 197.9 ± 14.10 |
| D     | 10 | 237.0 ± 9.78 | 239.7 ± 8.12 | 241.0 ± 7.75 | 243.3 ± 6.92 | 243.6 ± 6.55 | 244.4 ± 6.43 |

n: Number of rats; D-5: Five days before the first administration of *A. fumigatus* spores; D-1: One day before the first administration of *A. fumigatus* spores; D0: The first administration day of *A. fumigatus* spores; D + 2: Two days after the first administration of *A. fumigatus* spores; D + 3: Three days after the first administration of *A. fumigatus* spores; D + 4: Four days after the first administration of *A. fumigatus* spores.

General observations
All experimental rats (groups A, B and C) had decreased appetite after immune inhibitor injection and fungal inoculation, and exhibited lethargy with dulling of their fur. On the second day after the first fungal inoculation, sneezing and nose scratching were observed in each group. Table 3 and Figure 3 illustrate the changes in rat weights throughout the experiment. Groups A, B and C, which were immunosuppressed and inoculated with *A. fumigatus*, had a gradual decline in average weight (P < 0.05), but no significant differences in body weight changes were found between the three groups (P > 0.05). Weights in group D had an increasing trend throughout the entire experiment (P < 0.05).

Absolute neutrophil count
For groups A, B and C, the neutrophil quantities on D0 were less than 0.1 × 10⁹/L, which were lower than the neutrophil counts for group D ((3.7 ± 1.84) × 10⁹/L).

Histopathological examination
AIFR affected 90% (9/10) of the rats in group A, 50% (5/10) in group B, and 10% (1/10) in group C (Figure 4). The fungal infection rate of group A was significantly higher than that of group B (P > 0.05) and group C (P < 0.05). Only one case of AIFR was established in group C, which had an infection rate that was significantly lower than that of group A (P < 0.05) but not group B (P > 0.05). No AIFR was found in group D.

According to our study, the rat nasal septum was the most susceptible site to *A. fumigatus* hyphae, followed by the turbinate, ethmoidal sinus and maxillary sinus (Figure 5). The AIFR rats in group A had a heavy *A. fumigatus* hyphal invasion. The nasal and sinus mucosa contained a large number of fungal components (Figure 5), which caused fungal vasculitis (Figure 6), vascular embolism, hemorrhage, and coagulative necrosis. Simultaneously, bone resorption (caused by the direct intrusion of hyphal masses) was observed without obvious infiltration of inflammatory cells or osteoclast cells near extremely necrotic tissue (Figure 5A, B, C). The hyphae were shaped like antlers, which is a morphological feature of *A. fumigatus*. Large numbers of fungal components and pyogenic granulomas were also seen in the pulmonary tissue of two rats in group...
A lower number of fungal components were found in group B. In addition, only a few invading *A. fumigatus* hyphae were seen in one of the rats belonging to group C. No lung was infected by *A. fumigatus* in groups B or C, and invasion was not found in the brain, liver, kidney or spleen of any group.

Different degrees of epithelial hyperplasia, disorder, and loss, in addition to gland hypertrophy, were found in all the experimental rats. No animal died prior to the euthanization stage.

**Observation of mast cells in AIFR**

MCs were identified by both metachromatic staining with toluidine blue and immunohistochemical staining for trypsin. Using toluidine blue, MCs were identified in tissue sections by their characteristic granular, deep blue-purple metachromatic appearance against blue orthochromatic background tissue (Figure 8). With the trypsin immunohistochemical stain, MCs were identified by dark-brown staining (Figure 9). Compared with the normal nasal cavity (Figure 10), the total number of MCs in *A. fumigatus* invasion areas was not increased. MC degranulation, on the other hand, was only found in or around regions of fungal invasion. While connective tissue around rat noses showed more MC infiltration than nasal cavities, no degranulation was observed in such areas (Figure 11).

**Discussion**

We successfully established an AIFR rat model that was stable and easy to operate by utilizing the administration of CPA and CA with subsequent nasal obstruction and fungal inoculation, which allowed us to research MC response to AIFR. This model is based on the development of rat models for bacterial rhinosinusitis and invasive pulmonary aspergillosis [13-17,19,20,22,23]. According to the clinical diagnosis of AIFR, we used the following categories to determine whether the model was successful: general response, immune status, and histopathological examination.

In our study, rats in group A, which were inoculated with $5 \times 10^7$ conidia/ml of *A. fumigatus*, had the highest AIFR incidence (90%), followed by rats in group B (50%) and group C (10%). No AIFR occurred in group D. Also, several infiltrating and degranulating MCs were found in regions infected with *A. fumigatus* hyphae. These results indicate that *A. fumigatus* concentration played an important role in the occurrence and development of AIFR, and MCs may have an effect on this disease process.

In our study, we chose SD rats, which were bred with Wistar rats, as the experimental animal, because they are more genetically stable than Wistar. Compared with rabbits and other large animals, rats are less expensive and easier to handle. In addition, they have more blood volume than mice, which is necessary for the repeated sampling of large quantities of blood in this study. Also, based on our pre-experiments, it was difficult to insert Merocel sponges into mouse nasal cavities, and instillation of *A. fumigatus* into mice without previously
inserting Merocel sponges caused lung fungal infections more frequently than AIFR.

Because AIFR occurs mainly in immunodeficient patients, we chose to first immunosuppress rats in order to simulate clinical AIFR. Our immunosuppression procedure was based on utilizing CPA in combination with CA. The selection of dosage for CPA and CA was based on a large number of pre-experiments in addition to the results of various articles researching invasive pulmonary aspergillosis in rats [37-41]. CPA is an alkylating agent from the

**Figure 5** A. fumigatus hyphae invasion in sinus cavity mucosa of rat with acute invasive fungal rhinosinusitis (AIFR). Bone resorption is caused by the intrusion of hyphal masses. The hyphae are antler-like. (A1. Hematoxylin and eosin staining, ×20; A2. Hematoxylin and eosin staining, ×40; B1. Periodic acid-Schiff staining, ×10; B2. Periodic acid-Schiff staining, ×40; C. Methenamine silver staining, ×40; D. MUC5B staining, ×40).

**Figure 6** Vascular invasion of A. fumigatus hyphae in sinus of rat with acute invasive fungal rhinosinusitis (AIFR). (A. Hematoxylin and eosin staining, ×40; B. Periodic acid-Schiff staining, ×40; C. Methenamine silver staining, ×40; D. MUC5B staining, ×40).
oxazaphosphorine group, an immunosuppressant that is widely used in clinical practice [42]. Unfortunately, CPA intake is associated with many serious side effects and toxicity, including mutagenicity, myelosuppression, cardiac toxicity, lung toxicity and urototoxicity, which are mainly mediated by reactive oxygen species and lipid peroxide formation [43,44]. In our preliminary studies, large doses of CPA induced hematuria in rats, and the mortality rate was high.

CA is a type of adrenal cortical hormone with immunosuppressive effects, which can aggravate fungal infections. By adding CA to our immunosuppression procedure, we were able to reduce the dosage of CPA and, thus, rat mortality, which improved the success rate of establishing an AIFR rat model. Several papers have reported that an invasive pulmonary aspergillosis (IPA) rat model can be established under neutropenic conditions (<0.1 × 10⁹/L on the day of

**Figure 7** Abundant *A. fumigatus* hyphae in lung tissue of group A. (A1. Hematoxylin and eosin staining, ×10; A2. Hematoxylin and eosin staining, ×40; B1. Periodic acid–Schiff staining, ×10; B2. Periodic acid–Schiff staining, ×40; C1. Methenamine silver staining, ×10; C2. Methenamine silver staining, ×40).

**Figure 8** A. Mast cell (MC) degranulation in hyperplastic mucosa of rat maxillary sinus invaded by *A. fumigatus* (Toluidine blue staining, ×40). B. Mast cell (MC) degranulation in rat nasal septum invaded by *A. fumigatus* (Toluidine blue staining, ×40). Red arrow indicates MC degranulation. Black arrow indicates *A. fumigatus* hyphae.
fungal inoculation) [37,38]. In our study, the neutrophil counts on D0 were also less than $0.1 \times 10^9$/L. After immunosuppression, all experimental rats demonstrated decreased energy and appetite, in addition to dulling of the fur and weight lost. Under these immunosuppressive conditions, we were able to successfully establish an AIFR rat model with no rat mortality.

In humans, ostiomeatal obstruction is a key precipitating factor in the pathogenesis of sinusitis. Obstructing the ventilation and drainage of the nasal cavity and sinus is one of the major virulence factors of fungal sinusitis. Clinically, the Merocel sponge is often used for patients with epistaxis or after nasal surgery. It has good tissue compatibility and rarely damages the nasal mucosa. Also, it is easy to insert into the nasal cavity and is difficult to prolapse. In 2008, a rabbit model of chronic rhinosinusitis was developed using Merocel sponges, which demonstrated that the Merocel sponge can remain in

Figure 9 Tryptase immunohistochemical staining for mast cell (MC) infiltration and degranulation in rat nasal mucosa invaded by *A. fumigatus*. Both tryptase-positive MCs and tryptase-positive granules are stained dark brown. (Original magnification ×40 in A, ×20 in C, and ×100 in B and D). Red arrow indicates MC infiltration and degranulation. Black arrow indicates *A. fumigatus* hyphae.

Figure 10 Mast cell (MC) infiltration in normal rat turbinate of group D. (A. Toluidine blue staining, ×20; B. Tryptase immunohistochemical staining for MC infiltration, ×20).
the nasal cavity for a lengthy period of time [45]. In 2010, Jin et al. reported that bacteria can cause rhinosinusitis under the condition of nasal obstruction with Merocel sponges, while bacteria alone cannot induce rhinosinusitis [15]. Nasal obstruction by Merocel sponges closely mimics the natural course of anthropic invasive fungal rhinosinusitis (IFRS) without surgical damage to local bone or mucosal integrity [24]. These reasons, along with its ease of manipulation, support the use of Merocel sponges in rhinosinusitis studies.

Aspergillus is one of the main pathogens found in patients with AIFR [3,46]. There are almost 900 species of Aspergillus in nature, and A. fumigatus is the most common one in humans [12]. These organisms are normally found in dust, soil, and the upper respiratory mucosa of healthy individuals. Generally, in healthy individuals, these spores are quickly eliminated by the immune system. However, in immunocompromised patients, inhalation of A. fumigatus may lead to AIFR.

Based on a large number of pre-experiments, various concentrations of fungal conidia have different effects on the rat sinus. An A. fumigatus concentration of $1 \times 10^8$ conidia/ml caused a high mortality rate (>50%). Consequently, we chose $5 \times 10^7$, $1 \times 10^7$ and $1 \times 10^6$ conidia/ml concentrations of A. fumigatus as the spore suspensions for this study, and we subsequently compared their different effects on establishing an AIFR rat model.

At present, only two papers reporting on an AIFR animal model have been published. In 2007, Rodriguez et al. developed a mouse model of AIFR through depleting neutrophils using anti-Gr-1 monoclonal antibody combined with the intranasal administration of A. fumigatus [5]. In this experiment, they failed to successfully utilize CPA in developing their animal model, which may be related to an inappropriate dose of cyclophosphamide. In contrast to this study, we immunosuppressed experimental rats by using CPA and CA, which are easily obtainable, commonly used immune inhibitors in the clinic. In 2013, a group of researchers established a rat model of AIFR [24]. They obstructed the rat nasal cavity with Merocel sponges for 5 days, and then injected CPA for immunosuppression, followed by inoculating A. fumigatus for a week. The entire experiment lasted for 18 days. In contrast, we developed a novel method to establish an AIFR rat model that better simulates the disease process in humans. In order to mimic the clinical process of AIFR formation, we injected rats with immune inhibitors first, and then inserted Merocel sponges into the rats’ nasal cavities, followed by inoculating A. fumigatus for three days. The entire experimental process lasted for only nine days. Compared with the two published studies, our methods are easier to operate and provided a stable fungal infection rate.

MCs, which play key roles in innate and adaptive immunity, are important effector cells in protective immune responses against pathogens [28-32]. While increasingly more data indicate that MCs play a crucial role in host defense, especially against bacteria [29], very little is known about the relevance of MC effects in fungal infections. In addition, no study has reported on the role of MCs in AIFR. Here, we observed the changes of MCs in AIFR rats. Toluidine blue, which is reliable in identifying MCs, and immunohistochemical staining for tryptase, which is a highly sensitive and specific method for MC identification [47], were used in this study. We observed that the total number of MCs in A. fumigatus invasion areas were not increased compared to normal rat nasal cavities. Even with low quantities, MC degranulation was found only in regions of A. fumigatus invasion or nearby perivascular areas. This indicates that the main role of MCs may not consist of direct phagocytosis after migration to fungal infection zones in AIFR, but instead may involve degranulation or the release of cytokines and chemokines involved in innate and adaptive immunity. Several researchers have reported that the functional status of MCs is represented by MC degranulation, and the ability of MCs to degranulate in
response to various stimuli is the very basis for their biological activity [48]. Through degranulation, MCs release several classes of preformed mediators, including histamine and proteases, contributing to host defense. In addition, MCs also employ numerous de novo synthesized mediators, many of which have been shown to be involved in protective host responses to fungal pathogens, such as IFN-γ [49].

Conclusions

Various fungal concentrations have different effects on establishing an AIFR rat model. The optimal fungal concentration plays an important role in the course of formation and development of AIFR. By inoculating a suspension of 5 x 10^7 conidia/ml, a stable AIFR rat model that is easy to operate can be established successfully. The MC data of the present study indicate that MCs may mainly play a role through degranulation or the release of cytokines and chemokines involved in innate and adaptive immunity, instead of direct phagocytosis of fungi in AIFR. The immunoregulatory role of MCs in both protective and destructive AIFR immune responses should be further evaluated, and detailed studies of MC function will enable the development of more effective therapies for AIFR via MC manipulation. Our AIFR rat model can be used to study the nasal immune mechanisms against A. fumigatus, and may be useful for the research of AIFR and MCs in the future.

Competing interests

The author(s) declare that they have no competing interests.

Authors’ contributions

YY wrote the paper in addition to performing the entire experimental procedure. ZZ participated in the experimental design. HW participated in paraffin sectioning. RW participated in part of the experimental establishment of the AIFR animal model. JF participated in the manuscript revision. HL participated in experimental design and coordination, and assisted in drafting the manuscript. All authors read and approved the final manuscript.

Acknowledgement

This work was supported in part by the Fungi and Fungal Disease Research Center of Peking University and Department of Pathology, Beijing Tongren Hospital and National Natural Science Foundation of China (No.81070769).

Author details

1. Department of Pathology, Affiliated Beijing Tongren Hospital, Capital Medical University, Beijing 100730, People’s Republic of China.
2. Department of Dermatology, First Hospital, Peking University, Beijing 100034, People’s Republic of China.
3. Department of ENT, Affiliated Beijing Tongren Hospital, Capital Medical University, Beijing 100730, People’s Republic of China.

Received: 24 June 2014 Accepted: 11 December 2014

Published online: 20 December 2014

References

1. Seo J, Kim HI, Chung SK, Kim E, Lee H, Choi JW, Cha JH, Kim HI, Kim ST: Cervicofacial tissue infarction in patients with acute invasive fungal sinusitis: prevalence and characteristic MR imaging findings. Neuroradiology 2013, 55:467–473.
2. Donovan ST, Thompson JW, Sandlund JT, Adderson EE, Pilnick EK, Harrell JH: Imaging of acute invasive fungal rhinosinusitis in a patient with gorlin syndrome and acute lymphocytic leukemia. Case Rep Otolaryngol 2013, 2013:272314.
3. Tarkan O, Karagun B, Odeyemi S, Tuncer U, Summeloglu O, Cekic E, Kara K: Endonasal treatment of acute invasive fungal rhinosinusitis in immunocompromised pediatric hematolology-oncology patients. Int J Pediatr Otorhinolaryngol 2012, 76:1458–1464.
4. Arndt S, Aschenhoff A, Echternach M, Daemmrich TD, Maier W: Rhino-orbital-cerebral mucormycosis and aspergillosis: differential diagnosis and treatment. Eur Arch Oto-rhino-laryngol Off J Eur Fed Oto-Rhino-Laryngol Soc 2009, 266:71–76.
5. Rodriguez TE, Falkowski NR, Harkema JR, Huffnagle GB: Role of neutrophils in preventing and resolving acute fungal sinusitis. Infect Immun 2007, 75:5665–5668.
6. Sundaran C, Mahadevan A, Laeni V, Yasha TC, Santosh V, Murthy JM, Parooth AK, Mohandas S, Shankar SK: Cerebral zygomycosis. Mycoses 2005, 48:396–407.
7. Schechenbach K, Comely O, Hoffmann TK, Enges R, Bier H, Chaker A, Greve J, Schipper J, Wagenmann M: Emerging therapeutic options in fulminating invasive rhinocerebral mucormycosis. Auris Nasus Larynx 2010, 37:322–328.
8. Parikh SI, Venkatraman P, DeCausio JM: Invasive fungal sinusitis: a 15-year review from a single institution. Am J Rhinol 2004, 18:75–81.
9. Mohindra S, Mohindra S, Gupta R, Bakhri L, Gupta SK: Rhinocerebral mucormycosis: the disease spectrum in 27 patients. Mycoses 2007, 50:290–296.
10. Suslu AE, Ogemtepeoglu O, Suslu N, Yucel OT, Onerci TM: Acute invasive fungal rhinosinusitis: our experience with 19 patients. Eur Arch Oto-Rhino-laryngol Off J Eur Fed Oto-Rhino-Laryngol Soc 2009, 266:877–82.
11. Eliahar R, Nesnick IB, Goldfarb A, Wohlgelernter J, Gross M: Endoscopic surgery for sinonasal invasive aspergillosis in bone marrow transplantation patients. Laryngoscope 2007, 117:78–81.
12. Monroe MM, McLean M, Sautter N, Wax MK, Andersen PE, Smith TL, Gross ND: Invasive fungal rhinosinusitis: a 15-year experience with 29 patients. Laryngoscope 2013, 123:1583–1587.
13. Selicuk A, Akdogan G, Gayar SG, Ozcan KM, Ozcan I, Deree H, Ensari S, Ozogul C: Analysis of lower airway inflammation in a rabbit model of acute rhinosinusitis. Indian J Otolaryngal Head Neck Surg: off Publ Assoc Otolaryngol India 2011, 63:119–125.
14. Wang Y, Chen S, Chen J, Zhang W, Gong G, Zhou T, Kong W: Bacterial biofilm formation after nasal packing in nasal mucosa-wounded mice. Am J Rhinol Allergy 2013, 27:e91–e95.
15. Jin M, Gu Z, Bian Z, Yang I, Cao Z, Yu X, Guo G: Developing a mouse model of acute bacterial rhinosinusitis. Eur Arch Oto-Rhino-laryngol Off J Eur Fed Oto-Rhino-Laryngol Soc 2011, 268:857–861.
16. Wang H, Lu X, Cao PP, Chu Y, Long XB, Zhang XH, You XJ, Cui YH, Liu Z: Histological and immunological observations of bacterial and allergic chronic rhinosinusitis in the mouse. Am J Rhinol 2008, 22:934–948.
17. Krespi YP, Kahnir V, Kara CO: Laser-induced microbial reduction in acute bacterial rhinosinusitis. Am J Rhinol Allergy 2009, 23:629–632.
18. Capilla J, Clemons KV, Stevens DA: Animal models: an important tool in mycology. Med Mycol 2007, 45:657–684.
19. Zhao Y, Park S, Warn P, Shrifl R, Harrison E, Perlin DS: Detection of Aspergillus fumigatus in a rat model of invasive pulmonary aspergillosis by real-time nucleic acid sequence-based amplification. J Clin Microbiol 2010, 48:1379–1383.
20. Lo Giudice P, Campo S, De Santis R, Salvatori G: Effect of PTX3 and voriconazole combination in a rat model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother 2012, 56:6400–6402.
21. Dufour X, Kauffmann-Lacroix C, Goujon JM, Groller G, Rodier MH, Nossek JM: Experimental model of fungal sinusitis: a pilot study in rabbits. Ann Otol Rhinol Laryngol 2005, 114:167–172.
22. Clemons KV, Schwartz IA, Stevens DA: Therapeutic and toxicologic studies in a murine model of invasive pulmonary aspergillosis. Med Mycol 2011, 49:834–847.
23. Chandenier J, Bernard S, Monthur J, Baillly E, Feissot F, de Monte M, Desoubeaux G, Diot P, Richard-Lebonle D: The utility of a nebulised intra-tracheal rat model of invasive pulmonary aspergillosis. Mycoses 2009, 52:239–245.
24. Zhang F, An Y, Li Z, Zhao C: A novel model of invasive fungal rhinosinusitis in rats. Am J Rhinol Allergy 2013, 27:361–366.
25. Epstein VA, Kern RC: Invasive fungal sinusitis and complications of rhinosinusitis. Otolaryngol Clin N Am 2008, 41:497–524.
26. Utb M, Sheppard DC: The role of mast cells in the defence against pathogens. Clin Pathog 2012, 8:e1002619.
27. Moon TC, St Laurent CD, Morris KE, Marcet C, Yoshimura T, Sekar Y, Beuf AD: Advances in mast cell biology: new understanding of heterogeneity and function. *Mucosal Immunol* 2010, 3:111–128.

28. Malaviya R, Ross EA, MacGregor J, Ikeda T, Little JR, Jakschik BA, Abraham SN: Mast cell phagocytosis of FimH-expressing enterobacteria. *J Immunol* 1994, 152:1907–1914.

29. Abraham SN, St John AL: Mast cell-orchestrated immunity to pathogens. *Nat Rev Immunol* 2010, 10:440–452.

30. Galli SJ, Kalesnikoff J, Grimaldieston MA, Piliopksny AM, Williams CM, Tsai M: Mast cells as "tunable" effector and immunoregulatory cells: recent advances. *Annu Rev Immunol* 2005, 23:749–786.

31. Marshall JS: Mast-cell responses to pathogens. *Nat Rev Immunol* 2004, 4:787–799.

32. Dawicki W, Marshall JS: New and emerging roles for mast cells in host defence. *Curr Opin Immunol* 2007, 19:31–38.

33. Ulb M, Poulter P, Gravelat FN, Olivier M, Sheppard DC: *Aspergillus fumigatus* induces immunoglobulin E-independent mast cell degranulation. *J Infect Dis* 2009, 200:464–472.

34. Takabayashi T, Kato A, Pets AT, Suh LA, Carter R, Njorton J, Grammer LC, Tan BK, Chandra RK, Conley DR, Kern RC, Fujieda S, Schleimer RP: Glandular mast cells with distinct phenotype are highly elevated in chronic rhinosinusitis with nasal polyps. *J Allergy Clin Immunol* 2012, 130:410–420; e415.

35. Cao P, Hua X, Liu Z, Chu H, Cui Y: Mast cell and its relation to eosinophilic inflammation in CRSsNP. *Liu Chuang er bi yan hou tou jing wai ke za zhi = J Clin Otorhinolaryngol Head Neck Surg* 2010, 24:921–929.

36. Pawankar R: Mast cells in allergic airway disease and chronic rhinosinusitis. *Chem Immunol Allergy* 2005, 87:111–129.

37. van de Sande WW, van Vianen W, ten Kate MT, Vissers J, Laurijsens J, Tavakol M, Rijnders BJ, Mathot RA, Bakker-Woudenberg IA: *Caspofungin* prolongs survival of transiently neutropenic rats with advanced-stage invasive pulmonary aspergillosis. *Antimicrob Agents Chemother* 2008, 52:1345–1350.

38. van Vianen W, de Marie S, ten Kate MT, Mathot RA, Bakker-Woudenberg IA: *Caspofungin*: antifungal activity in vitro, pharmacokinetics, and effects on fungal load and animal survival in neutropenic rats with invasive pulmonary aspergillosis. *J Antimicrob Chemother* 2006, 57:732–740.

39. Lewis RE, Albert ND, Kontoyiannis DP: Comparison of the dose-dependent activity and paradoxical effect of caspofungin and micafungin in a neutrophilic murine model of invasive pulmonary aspergillosis. *J Antimicrob Chemother* 2008, 61:1140–1144.

40. Niki Y, Bernard EM, Edwards FF, Schmitt HJ, Yu B, Armstrong D: Model of recurrent pulmonary aspergillosis in rats. *J Clin Microbiol* 1991, 29:1317–1322.

41. Howard SJ, Listner JM, Sharp A, Gregson L, Goodwin J, Slater J, Majithiya JB, Warn PA, Hope WW: Pharmacokinetics and pharmacodynamics of posaconazole for invasive pulmonary aspergillosis: clinical implications for antifungal therapy. *J Infect Dis* 2011, 203:1324–1332.

42. Ramadan G, El-Beih NM, Zahra MM: Egyptian sweet marjoram leaves protect against genotoxicity, immunosuppression and other complications induced by cyclophosphamide in albino rats. *British J Nutr* 2012, 108:1059–1068.

43. Bhatia K, Kaur M, Atif F, Ali M, Rehman H, Rahman S, Raisuddin S: Aqueous extract of Trigonella foenum-gaecum L. ameliorates additive urotoxicity of buthionine sulfoximine and cyclophosphamide in mice. *Food Chem Toxicol: Int J Brit Ind Biol Res Assoc* 2006, 44:1744–1750.

44. Arafa HM: Uroprotective effects of curcumin in cyclophosphamide-induced haemorrhagic cystitis paradigm. *Basic Clin Pharmacol Toxicol* 2009, 104:393–399.

45. Liang KL, Jiang RS, Wang J, Shiao JY, Su MC, Hsin CH, Lin JF: Developing a rabbit model of rhinogenic chronic rhinosinusitis. *Laryngoscope* 2008, 118:1075–1081.

46. Ghoshal MT, Deckard NA, Farooq U, Astor F, Robinson P, Casiano RB: Frozen-section biopsy analysis for acute invasive fungal rhinosinusitis. *Otolaryngol–Head Neck Surgery: Off J Am Acad Otolaryngol-Head Neck Surg* 2007, 136:714–719.

47. Walls AF, Jones DB, Williams JH, Church MK, Holgate ST: Immunohistochemical identification of mast cells in formaldehyde-fixed tissue using monoclonal antibodies specific for tryptase. *J Pathol* 1990, 162:119–126.

48. Mauer M, Theohardes T, Granstein RD, Bischoff SC, Bienenstock J, Henz B, Kovanen P, Piliponsky AM, Kambe N, Vilagofsht I, Levi-Schaffer F, Metz M, Miyachi Y, Befus D, Forysthe P, Kitamura Y, Galli S: What is the physiological function of mast cells? *Exp Dermatol* 2003, 12:886–910.

49. Saluja R, Metz M, Maurer M: Role and relevance of mast cells in fungal infections. *Front Immunol* 2012, 3:146.